3 recruiting, 2 not yet recruiting, 1 suspended, 1 withdrawn. 7 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 7 | Recruiting 3, Not yet recruiting 2, Suspended 1, Withdrawn 1 |
Follow ANCA Associated Vasculitis: new trials by email Literature Review of ANCA Associated Vasculitis trials Research Report on ANCA Associated Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases RD06-05 CAR-T Cell Injection - SLE - Systemic Lupus Erythematosus, Systemic Sclerosis | Early Phase 1 | Not yet recruiting | Nanjing Bioheng Biotech Co., Ltd. | 30 | 2026-09-01 | 2026-07-16 |
| Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases BCT301 - System Lupus Erythematosus, Systemic Sclerosis (SSc) | Early Phase 1 | Recruiting | Peking University Third Hospital | 10 | 2025-12-11 | 2026-09-23 |
| A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. RD06-05 CART Cell Injection - SLE, LN | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 96 | 2025-07-24 | 2026-08-03 |
| Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases CD19 or CD19-BCMA CAR-T - SLE (Systemic Lupus), Systemic Sclerosis | Early Phase 1 | Recruiting | Nanjing Bioheng Biotech Co., Ltd. | 20 | 2024-09-14 | 2026-03-06 |
| Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases RD06-04 CART Cell Injection - Systemic Lupus Erythematosus, Systemic Sclerosis | Early Phase 1 | Suspended | Nanjing Bioheng Biotech Co., Ltd. | 12 | 2024-09-13 | 2026-02-03 |
| A Study of RD06-04 in Patients With Active Autoimmune Diseases RD06-04 cell infusion - SLE, Sclerosis | Early Phase 1 | Withdrawn | Nanjing Bioheng Biotech Co., Ltd. | 2024-08-31 | 2026-02-03 | |
| The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases anti-CD19-CAR-T cells - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome | Early Phase 1 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 9 | 2024-05-27 | 2024-05-17 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (7) · Lupus Erythematosus, Systemic (5) · Scleroderma, Systemic (5) · Sjogren's Syndrome (5) · Myositis (4) · Autoimmune Diseases (3) · Antiphospholipid Syndrome (2) · Anti-Glomerular Basement Membrane Disease (1) · Glomerulonephritis, IGA (1) · Neuromyelitis Optica (1) · Sclerosis (1)
Cardiovascular Diseases (7) · Immune System Diseases (7) · Skin Diseases (7) · Skin Diseases, Vascular (7) · Skin and Connective Tissue Diseases (7) · Systemic Vasculitis (7) · Vascular Diseases (7) · Vasculitis (7) · Eye Diseases (6) · Arthritis (5) · Arthritis, Rheumatoid (5) · Connective Tissue Diseases (5) · Dry Eye Syndromes (5) · Joint Diseases (5) · Lacrimal Apparatus Diseases (5)
Antigens, CD19 (1)
Nanjing Bioheng Biotech Co., Ltd. (5) · First Affiliated Hospital of Wenzhou Medical University (1) · Peking University Third Hospital (1)
China (7)
LI Sun, Master's (1) · Qiong Fu, Doctor (1)